Changes of Hepcidin During Anemia Treatment in Patients on Maintenance Hemodialysis

LIU Yu-xia,ZHU Li-qin,LIU Na,FANG Lu,LI Xiao-jun,YAN Haidong,ZHUANG shougang
DOI: https://doi.org/10.3969/j.issn.1671-4091.2014.06.010
2014-01-01
Abstract:Objective This study was to investigate the changes of hepcidin during anemia treatment and its interaction with iron and erythropoietin(EPO) supplements in maintenance hemodialysis(MHD) patients, in order to explore the therapy for the recovery of iron homeostasis. Methods A total of 32 patients on MHD for more than 6 months were enrolled in this study. Hemoglobin was lower than 110 g/l in these patients. They were treated with iron and EPO supplements. Serum hepcidin was measured by ELISA. Iron metabolism indices including serum Fe, serum ferritin(SF) and transferrin saturation(TSAT) were measured by routine methods. The correlations of hepcidin with iron metabolism indices, erythropoiesis, and supplements of iron and EPO were analyzed. Results Serum hepcidin level was significantly higher in MHD patients than in healthy controls(324±124.2 ng/l vs. 72.4±12.3 ng/l, P0.001). Serum hepcidin level was positively correlated with serum Fe(r=0.68, P=0.005), SF(r=0.62, P=0.004) and TSAT(r=0.7, P=0.001), and negatively correlated with reticulocyte count(r=-0.63, P=0.015). Regular hemodialysis can effectively remove hepcidin, and restore serum level to the original level in 2 weeks before hemodialysis. EPO administration rather than intravenous iron supplement could reduce serum hepcidin level. Conclusions Serum hepcidin increased in MHD patients. Higher serum hepcidin may contribute to the abnormal iron metabolism and erythropoiesis. Effective removal of hepcidin from the body and treatment with EPO can improve erythropoiesis and iron recycles, restore iron homeostasis, and prevent further damage due to iron overload.
What problem does this paper attempt to address?